Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001410578-24-001894
Filing Date
2024-11-12
Accepted
2024-11-12 17:16:03
Documents
73
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q eyen-20240930x10q.htm   iXBRL 10-Q 1695586
2 EX-10.7 eyen-20240930xex10d7.htm EX-10.7 118520
3 EX-10.8 eyen-20240930xex10d8.htm EX-10.8 113042
4 EX-31.1 eyen-20240930xex31d1.htm EX-31.1 14024
5 EX-31.2 eyen-20240930xex31d2.htm EX-31.2 13911
6 EX-32.1 eyen-20240930xex32d1.htm EX-32.1 7233
7 EX-32.2 eyen-20240930xex32d2.htm EX-32.2 7423
  Complete submission text file 0001410578-24-001894.txt   8255229

Data Files

Seq Description Document Type Size
8 EX-101.SCH eyen-20240930.xsd EX-101.SCH 66412
9 EX-101.CAL eyen-20240930_cal.xml EX-101.CAL 57607
10 EX-101.DEF eyen-20240930_def.xml EX-101.DEF 199150
11 EX-101.LAB eyen-20240930_lab.xml EX-101.LAB 449358
12 EX-101.PRE eyen-20240930_pre.xml EX-101.PRE 373318
76 EXTRACTED XBRL INSTANCE DOCUMENT eyen-20240930x10q_htm.xml XML 1516852
Mailing Address 295 MADISON AVENUE, SUITE 2400 NEW YORK NY 10017
Business Address 295 MADISON AVENUE, SUITE 2400 NEW YORK NY 10017 813-766-9539
EYENOVIA, INC. (Filer) CIK: 0001682639 (see all company filings)

EIN.: 471178401 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38365 | Film No.: 241449862
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)